Leading clinical research organization moves to the industry’s only unified platform to maximize efficiencies and outcomes
The eTMF deal represents a replacement of one of Medidata’s important competitors, while the CTMS agreement is a replacement of Aperio’s own legacy CTMS system. This agreement also is an expansion of their earlier deployment of Rave Coder and Medidata Rave®, the world’s leading solution for capturing, managing and reporting patient data.
“We selected Medidata for our EDC, eTMF and CTMS solutions because we
wanted a platform that could provide us a single source of truth with
excellent reporting capabilities allowing us to provide transparency to
our sponsors.” said
Expanding the use of Medidata’s unified solutions will enable Aperio to streamline their clinical operations by managing all study data and documents in a single secure platform. Medidata’s Clinical Cloud, the industry’s leading unified platform, will enable Aperio to manage their entire end-to-end clinical process in a consistent and secure platform thereby accelerating clinical development while dramatically reducing their trial cost and risk.
“Aperio’s decision to add our eTMF and CTMS solutions to their platform
is a reflection of the unique value that we are bringing to our
customers and partners who recognize the importance of unifying those
solutions on one platform,” said
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com
About Aperio Clinical Outcomes
Aperio Clinical Outcomes provides full, customizable clinical research services across multiple therapeutic areas. Dedicated to transparent interactions with clients, Aperio also offers consulting services in Quality Assurance, Strategic Resourcing, and practical application of the latest Clinical Trial Technology.
In an industry flooded with data, metrics and technology, Aperio remains steadfastly focused on the most important part of the process: people. From start-up to close out and every point in between, Aperio works with its partners to deliver outcomes that will improve patient care and save lives.
Aperio Clinical Outcomes.
We make it clear.
Investor: Betsy Frank, +1 917-522-4620
Anthony D’Amico, +1 732-767-4331
Erik Snider, +1 646-362-2997
Aperio Clinical Outcomes
Melissa Hancock, 919-680-1539